{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:39:35Z","timestamp":1788316775875,"version":"build-2803163510"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,30]],"date-time":"2022-08-30T00:00:00Z","timestamp":1661817600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018787","name":"Novartis Pharma AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.semarthrit.2022.152081","type":"journal-article","created":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T21:24:45Z","timestamp":1660166685000},"page":"152081","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration"],"prefix":"10.1016","volume":"56","author":[{"given":"Lykke M.","family":"\u00d8rnbjerg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0863-1352","authenticated-orcid":false,"given":"Louise","family":"Linde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Georgiadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon H.","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Lindstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Askling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Michelsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela Di","family":"Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan K.","family":"Wallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pavelka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Z\u00e1vada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Nissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gareth T.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Relas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Piril\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matija","family":"Tom\u0161i\u010d","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziga","family":"Rotar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arni Jon","family":"Geirsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eirik K.","family":"Kristianslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"van sder Horst-Bruinsma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Gitte","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Laas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florenzo","family":"Iannone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Addolorata","family":"Corrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Ciurea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria J.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catalin","family":"Codreanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nurullah","family":"Akkoc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozgul S.","family":"Gunduz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bente","family":"Glintborg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2022.152081_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2016-210770","article-title":"2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis","author":"Van Der Heijde","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0002","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0003","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215427","article-title":"Treatment response and drug retention rates in 24 195 biologic-na\u00efve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration","author":"\u00d8rnbjerg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0004","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2009.124446","article-title":"Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years\u2019 surveillance in the Danish nationwide DANBIO registry","author":"Glintborg","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0005","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2010.147744","article-title":"Predicting the outcome of ankylosing spondylitis therapy","author":"Vastesaeger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0006","doi-asserted-by":"crossref","DOI":"10.1002\/art.23333","article-title":"The comparative one-year performance of anti-turmor necrosis factor \u03b1 drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study","author":"Heiberg","year":"2008","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0007","doi-asserted-by":"crossref","DOI":"10.1002\/acr.20258","article-title":"Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group register","author":"Kristensen","year":"2010","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0008","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.141278","article-title":"Predictors of clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials","author":"Baraliakos","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0009","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2014-000017","article-title":"Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systematic review and meta-analysis","author":"Maneiro","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0010","article-title":"A new approach to defining disease status in ankylosing spondylitis: the bath ankylosing spondylitis disease activity index","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0011","article-title":"Assessment of ankylosing spondylitis","author":"Zochling","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0012","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2010.138883","article-title":"ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF\u03b1 inhibitors","author":"Pedersen","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0013","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2008.094870","article-title":"Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis","author":"Lukas","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0014","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2010.138594","article-title":"Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores","author":"MacHado","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","author":"Smolen","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0016","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.170166","article-title":"Response to tumor necrosis factor inhibition in male and female patients with ankylosing spondylitis: data from a Swiss Cohort","author":"Hebeisen","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/s42358-018-0040-x","article-title":"Factors associated with ASDAS remission in a long-term study of ankylosing spondylitis patients under tumor necrosis factor inhibitors","author":"Shimabuco","year":"2018","journal-title":"Adv Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0018","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/kez657","article-title":"Predicting response to anti-TNF\u03b1 therapy among patients with axial spondyloarthritis (axSpA): results from BSRBR-AS","author":"MacFarlane","year":"2020","journal-title":"Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0019","article-title":"Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA","author":"Brahe","year":"2020","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0020","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-213184","article-title":"ankylosing spondylitis disease activity score (ASDAS): 2018 update of the nomenclature for disease activity states","author":"Machado","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0021","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0022","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the bath ankylosing spondylitis functional index","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0023","first-page":"789","article-title":"The dimensions of health outcomes: the health assessment questionnaire, disability and pain scales","volume":"9","author":"Fries","year":"1982","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0024","doi-asserted-by":"crossref","DOI":"10.1002\/sim.3177","article-title":"How should variable selection be performed with multiply imputed data?","author":"Wood","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0025","series-title":"Flexible imputation of missing data","author":"Yang","year":"2018"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0026","article-title":"A comparison of logistic regression pseudo R2 indices","author":"Smith","year":"2013","journal-title":"Mult Linear Regres Viewpoints"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/bimj.201700067","article-title":"Variable selection \u2013 a review and recommendations for the practicing statistician","author":"Heinze","year":"2018","journal-title":"Biometrical J"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0028","doi-asserted-by":"crossref","DOI":"10.1148\/radiology.143.1.7063747","article-title":"The meaning and use of the area under a receiver operating characteristic (ROC) curve","author":"Hanley","year":"1982","journal-title":"Radiology"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0029","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-020-02337-2","article-title":"Differences between men and women with nonradiographic axial spondyloarthritis: clinical characteristics and treatment effectiveness in a real-life prospective cohort","author":"Neuenschwander","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0030","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2011-200358","article-title":"Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis","author":"Sieper","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0031","doi-asserted-by":"crossref","DOI":"10.1002\/acr.23465","article-title":"Profiling response to tumor necrosis factor inhibitor treatment in Axial Spondyloarthritis","author":"Alazmi","year":"2018","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0032","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.170477","article-title":"Comparative analysis and predictors of 10-year tumor necrosis factor inhibitors drug survival in patients with spondyloarthritis: first-year response predicts longterm drug persistence","author":"Flouri","year":"2018","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0033","article-title":"Remission in ankylosing spondylitis treated with anti-TNF-\u03b1 drugs: a national multicentre study","author":"Spadaro","year":"2013","journal-title":"Rheumatol (United Kingdom)"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0034","article-title":"Clinical response, drug survival and predictors thereof in 432 ankylosing spondylitis patients after switching tumour necrosis factor \u03b1 inhibitor therapy: results from the Danish nationwide DANBIO registry","author":"Glintborg","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0035","doi-asserted-by":"crossref","DOI":"10.1007\/s10067-020-05319-6","article-title":"Influence of smoking and obesity on treatment response in patients with axial spondyloarthritis: a systematic literature review","author":"Zurita Prada","year":"2021","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2022.152081_bib0036","article-title":"European bio-na\u00efve spondyloarthritis patients initiating TNFi: time trends in baseline characteristics, treatment retention and response","author":"Christiansen","year":"2021","journal-title":"Rheumatol (United Kingdom)"}],"updated-by":[{"DOI":"10.1016\/j.semarthrit.2022.152141","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000}}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001329?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017222001329?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T13:32:05Z","timestamp":1708781525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017222001329"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":36,"alternative-id":["S0049017222001329"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152081","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.semarthrit.2022.152141","asserted-by":"object"}]},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictors of ASDAS-CRP inactive disease in axial spondyloarthritis during treatment with TNF-inhibitors: Data from the EuroSpA collaboration","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2022.152081","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"152081"}}